Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rahu Catalytics is a specialty chemicals and biotechnology company that originated as a spin-out from Unilever Ventures. The company specializes in the development and commercialization of high-performance manganese-based catalysts, most notably the "Dragon" and "Pegasus" ligand technologies. These catalysts function as biomimetic oxidation systems, effectively acting as artificial enzymes for a variety of applications. While widely used in industrial coatings and detergents, the technology is also critical in the life sciences for the efficient synthesis of pharmaceutical intermediates and the development of sustainable chemical processes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rahu Catalytics.